Table 6.

Efficacy evaluation on D28 after PCR correction by center (ITT population)

Clinical evaluation	ASAQ1 (N = 310)	ASAQ2 (N = 315)	AL (N = 311)	Total (N = 936)
Cameroon
Possible failure (information unavailable)	3 (5.6%)	8 (14.5%)	4 (7.1%)	15 (9.1%)
Early treatment failure	0	0	0	0
Late clinical failure	0	0	0	0
Late parasitological failure	0	0	0	0
Adequate clinical and parasitological response	51 (94.4%)	47 (85.5%)	52 (92.9%)	150 (90.9%)
Madagascar
Possible failure (information unavailable)	0	2 (3.3%)	0	2 (1.1%)
Early treatment failure	0	0	0	0
Late clinical failure	0	0	1 (1.7%)	1 (0.6%)
Late parasitological failure	1 (1.7%)	0	0	1 (0.6%)
Adequate clinical and parasitological response	58 (98.3%)	58 (96.7%)	59 (98.3%)	175 (97.8%)
Mali
Possible failure (information unavailable)	2 (3.0%)	3 (4.4%)	2 (3.0%)	7 (3.5%)
Early treatment failure	0	0	0	0
Late clinical failure	0	0	0	0
Late parasitological failure	2 (3.0%)	0	2 (3.0%)	4 (2.0%)
Adequate clinical and parasitological response	62 (93.9%)	65 (95.6%)	63 (94.0%)	190 (94.5%)
Senegal – Keur Soce
Possible failure (information unavailable)	2 (2.1%)	1 (1.1%)	2 (2.2%)	5 (1.8%)
Early treatment failure	0	0	0	0
Late clinical failure	0	0	0	0
Late parasitological failure	0	0	1 (1.1%)	1 (0.4%)
Adequate clinical and parasitological response	93 (97.9%)	91 (98.9%)	86 (96.6%)	270 (97.8%)
Senegal – Mlomp
Possible failure (information unavailable)	5 (13.9%)	2 (5.0%)	1 (2.6%)	8 (7.0%)
Early treatment failure	0	0	0	0
Late clinical failure	0	0	1 (2.6%)	1 (0.9%)
Late parasitological failure	0	0	0	0
Adequate clinical and parasitological response	31 (86.1%)	38 (95.0%)	37 (94.9%)	106 (92.2%)